InMed Pharmaceuticals Inc. INM
dollar amounts stated herein are in U.S. dollars unless specified otherwise.
are a pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands
of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part
of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $4.6M | $4.1M | $1.1M | $1.9M | — | — |
| Cost of revenue | $3.2M | $3.5M | $2.7M | $545.9K | — | — | — |
| Gross profit | $1.7M | $1.1M | $1.4M | $543.5K | — | — | — |
| R&D | $2.9M | $3.2M | $3.7M | $7.3M | $5.3M | $5.8M | — |
| SG&A | $6.6M | $5.8M | $5.8M | $6.9M | $4.5M | $3.2M | — |
| Total operating expenses | $9.7M | $9.3M | $9.8M | $17.8M | $9.9M | $9.2M | — |
| Operating income | — | — | -$7.9M | -$18.6M | -$10.2M | — | — |
| Interest expense | — | — | — | — | $360.4K | — | — |
| Pre-tax income | -$8.2M | -$7.7M | -$7.9M | -$18.6M | — | — | — |
| Income tax | — | $7.1K | $13.1K | — | — | — | — |
| Net income | -$8.2M | -$7.7M | -$7.9M | -$18.6M | -$10.2M | -$8.9M | — |
| EPS, basic | -8.36 | -20.14 | -3.25 | -33.17 | -37.96 | — | — |
| EPS, diluted | -8.36 | -20.14 | -3.25 | -33.17 | -37.96 | -1.71 | — |
| Shares, diluted (wtd. avg.) | $976.0K | $381.1K | $2.4M | $560.8K | $268.8K | $5.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.1M | $6.6M | $8.9M | $6.2M | $7.4M | $5.8M | $9.8M |
| Short-term investments | $43.4K | $43.1K | $44.4K | $44.8K | $46.5K | $42.4K | — |
| Receivables | $465.1K | $352.8K | $260.4K | $88.0K | $11.9K | $45.3K | — |
| Inventory | $961.2K | $1.2M | $1.6M | $2.5M | — | — | — |
| Total current assets | $12.9M | $8.7M | $11.3M | $9.6M | $8.4M | $6.3M | — |
| Property, plant and equipment | $992.2K | $1.2M | $723.4K | $904.3K | $326.6K | $403.5K | — |
| Other intangibles | $1.6M | $1.8M | $1.9M | $2.1M | $1.1M | $1.1M | — |
| Total assets | $15.6M | $11.8M | $14.1M | $12.8M | $9.8M | $7.8M | — |
| Accounts payable | $1.4M | $1.7M | $1.6M | $2.4M | $2.1M | $1.6M | — |
| Total current liabilities | $1.8M | $2.0M | $2.0M | $3.3M | $2.2M | $1.7M | — |
| Total liabilities | $2.1M | $2.6M | $2.0M | $3.7M | $2.4M | $1.9M | — |
| Retained earnings | -$117.2M | -$109.1M | -$101.4M | -$93.5M | -$74.9M | -$64.6M | — |
| Total equity | $13.4M | $9.2M | $12.1M | $9.1M | $7.4M | $5.9M | $14.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.8M | -$7.0M | -$7.3M | -$15.6M | -$9.8M | -$7.4M | — |
| Depreciation and amortisation | $212.8K | $219.6K | $202.2K | $185.7K | $120.9K | $112.4K | — |
| Stock-based compensation | $119.3K | $137.7K | $278.2K | $697.9K | $610.2K | $994.4K | — |
| Capital expenditure | $0 | $9.3K | $160.0K | $39.1K | $1.7K | $42.6K | — |
| Investing cash flow | $0 | -$9.3K | -$661.8K | -$673.0K | -$1.7K | $3.8M | — |
| Financing cash flow | $12.3M | $4.7M | $10.7M | $15.1M | $10.9M | -$31.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-294455.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |